Key facts
- ParcelBio’s last known valuation is $41.2M (Mar 2026).
- It has raised $13.7M across 1 recorded rounds; the latest was Seed Round in May 2024.
- Notable investors include Y Combinator, Alumni Ventures, Pioneer Fund, Metaplanet Holdings, 468 Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for ParcelBio
Funding rounds
1 roundsAbout ParcelBio
Developer of a programmable technology designed to deliver messenger ribonucleic acid to diverse cell types in the body. The company's technology leverages technology to create ribonucleic acid therapeutics that are more targeted, potent and durable than traditional drugs, enabling medical professionals to treat diseases such as cancer, genetic disorders and infectious diseases.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2023
- Employees
- 6
- Website
- parcelbio.com/
- Ownership
- Privately Held (backing)
ParcelBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ParcelBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ParcelBio in its N-PORT filings yet. We sweep new filings monthly.